Monotherapy Summary

• Improvements in glycemic control are associated with reductions in endogenous insulin, c-peptide, proinsulin, and insulin split products

• Avandia® has a durable effect for up to 12 months

Previous slide

Next slide

Back to first slide

View graphic version